Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 1.01 0.97 1.23

+8 more quarters

P/S ratio
4.26 4.92 3.94 5.13
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(3.49) (3.98) (8.44) (4.11)
P/B ratio
3.56 2.93 2.73 2.17
Price to Tangible BV
13.68 6.98 11.26 4.98
EV/Sales
6.35 5.88 4.89 5.68
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(1.74) (1.62) (1.49) (2.34)
EV/FCF
(1.73) (1.61) (1.48) (2.31)
Quick Ratio
1.58 1.43 1.36 1.19
Current Ratio
1.77 1.56 1.47 1.24
Net Debt/EBITDA
2.16 3.68 3.00 3.57
Debt/Assets
19.48% 13.96% 14.34% 7.16%
Debt/Equity
0.61 0.47 0.61 0.42
Asset Turnover
0.16 0.15 0.12 0.07
Operating CF/Net income
3.01 1.51 0.52 1.30
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
(13.92) (16.54) (20.40) (19.07)
Research and Development Expense of Revenue
149.87% 175.00% 242.97% 235.52%
Selling, General and Administrative Expense of Revenue
146.46% 187.68% 185.20% 215.46%
Intangible Assets out of Total Assets
0.24 0.17 0.18 0.10
Share Based Compensation of Revenue
18.05% 19.37% 21.84% 29.29%
Graham Net Nets
0.02 0.08 0.06 0.17
Graham Number
0.00 4.65 4.14 4.75
Earnings Yield
(73.57%) 98.82% 102.82% 81.10%
Free Cash Flow Yield
(86.26%) (74.41%) (83.84%) (47.81%)
Revenue per Share
0.09 0.09 0.11 0.10
Operating CF per Share
(0.40) (0.42) (0.17) (0.40)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.40) (0.42) (0.17) (0.40)
Cash per Share
0.68 1.22 1.47 1.65
Shareholders Equity per Share
0.39 0.58 0.52 0.76
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.39 0.58 0.52 0.76
Free Cash Flow
(62.09) (57.89) (19.72) (46.34)
Working Capital
58.28 73.70 66.32 88.66
Net Current Asset Value
3.44 18.64 9.38 32.21
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
66.95 42.47 70.38 224.65
Average Payables
25.40 26.20 19.19 23.39
Average Inventory
5.09 4.17 3.69 24.84
Average Assets
315.32 318.54 353.44 510.76
Average Common Equity
90.33 (52.42) (35.49) (0.10)

Fold the line items

Columns are period end dates